276 related articles for article (PubMed ID: 22238922)
1. [Strategies of breast cancer treatment based on determination of biological subtype].
Semiglazov VF
Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
[No Abstract] [Full Text] [Related]
2. [New approaches to the treatment of breast cancer].
Semiglazov VF
Vopr Onkol; 2013; 59(3):288-91. PubMed ID: 23909027
[No Abstract] [Full Text] [Related]
3. [Locally advanced breast cancer (methods of treatment)].
Portnoĭ SM
Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923
[No Abstract] [Full Text] [Related]
4. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
5. [Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
Bershteĭn LM; Semiglazov VF
Vopr Onkol; 2011; 57(5):559-66. PubMed ID: 22238924
[No Abstract] [Full Text] [Related]
6. [Systemic pharmacotherapy in breast cancer].
Boér K
Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
[No Abstract] [Full Text] [Related]
7. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
8. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Metzger-Filho O; de Azambuja E
J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant systemic therapy in breast cancer].
Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
[TBL] [Abstract][Full Text] [Related]
10. The HER2 World: Better Treatment Selection for Better Outcome.
Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
J Natl Cancer Inst Monogr; 2011; 2011(43):82-5. PubMed ID: 22043048
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
12. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
[TBL] [Abstract][Full Text] [Related]
13. Elucidating an uncommon disease: inflammatory breast cancer.
Crane K
J Natl Cancer Inst; 2011 Sep; 103(18):1358-60. PubMed ID: 21881039
[No Abstract] [Full Text] [Related]
14. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
15. [Sequencing of adjuvant treatment after surgery for invasive breast cancer].
Petit T; Claude L; Carrie C
Cancer Radiother; 2004 Feb; 8(1):54-8. PubMed ID: 15093202
[TBL] [Abstract][Full Text] [Related]
16. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
17. [Molecular subtypes and individualized treatment of breast cancer].
Xu BH; Zhang P
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):641-4. PubMed ID: 21122374
[No Abstract] [Full Text] [Related]
18. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
Tuma RS
J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
[No Abstract] [Full Text] [Related]
19. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
20. New research on the treatment of small HER2-positive breast cancers.
Krop IE
Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
